Viva Biotech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A CRO combining structural biology and AI for early-stage drug discovery, with a venture fund investing in client startups.
OncologyInfectious DiseaseNeurology
Technology Platform
Integrated platform combining advanced structural biology (cryo-EM, X-ray) with AI-driven computational chemistry for structure-based drug design.
Opportunities
Capitalizing on the industry's shift towards complex biological targets that require its specialized structural insights and AI capabilities.
Risk Factors
Revenue is project-dependent and susceptible to biotech funding cycles, and potential conflicts of interest could arise from its investment model.
Competitive Landscape
Competes with large global CROs on scale and with niche structural biology shops on scientific depth, with its equity model being a unique differentiator.